Optimising mRNA-LNP Drug Product Stability: Enhancing Quality & Reducing Aggregation for Clinical Readiness
Time: 10:00 am
day: Day Two
Details:
- How can lyophilisation techniques be refined to preserve mRNA-LNP integrity and quality, ensuring regulatory compliance and extended shelf life?
- What role do nebulising agents play in reducing LNP aggregation post-formulation, and how can this improve stability for regulatory readiness?
- How can lipid composition and excipient selection be tailored to minimise particle size variability and maximise encapsulation efficiency for stable and reproducible drug products?
